Vicapsys: Funding, Investors & Team (Oct 2026)
Vicapsys is a biotech firm that specializes in creating therapies for diabetes and other medical conditions. Its approach involves harnessing natural processes in a specific area to achieve positive treatment results without causing negative effects throughout the body. At the heart of Vicapsys' technology lies a versatile signaling molecule called CXCL12, which can be carefully formulated to achieve desired therapeutic effects for various medical indications. The company's current primary focus is on finding a cure for Type 1 diabetes by ensuring the long-term survival of transplanted islet cells. This is done through a formulation that prevents the body's immune response and provides protection to the transplanted cells.
Vicapsys has raised $330k across 1 funding round on record, the most recent an undisclosed round of $330k announced in Jul 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vicapsys Company Profile and Key Stats
Latest funding round on record: Jul 2023.
Vicapsys Funding Rounds
Vicapsys Founders and Leadership Team
Contact details for the Vicapsys team: 1 of 1 has an email address on file.
Start 14-day free trial →Vicapsys Funding Compared to Other Biotechnology Startups
Vicapsys' latest round of $330k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vicapsys in Biotechnology and Suwanee
Companies Similar to Vicapsys
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Vicapsys Funding FAQs
What does Vicapsys do?
Vicapsys is a biotech firm that specializes in creating therapies for diabetes and other medical conditions. Its approach involves harnessing natural processes in a specific area to achieve positive treatment results without causing negative effects throughout the body. At the heart of Vicapsys' technology lies a versatile signaling molecule called CXCL12, which can be carefully formulated to achieve desired therapeutic effects for various medical indications. The company's current primary focus is on finding a cure for Type 1 diabetes by ensuring the long-term survival of transplanted islet cells. This is done through a formulation that prevents the body's immune response and provides protection to the transplanted cells.
How much funding has Vicapsys raised?
Vicapsys has raised $330k across 1 round on record. The most recent is an undisclosed round of $330k announced in Jul 2023.
When did Vicapsys last raise funding?
Vicapsys' most recent funding round on record is an undisclosed round of $330k, announced in Jul 2023.
Who founded Vicapsys?
FundedIQ lists Federico Pier (Founder) at Vicapsys.
Where is Vicapsys headquartered?
Vicapsys is based in Suwanee, Georgia, United States.
How many employees does Vicapsys have?
Vicapsys is in the 1-10 employee band.
How does Vicapsys' funding compare to other Biotechnology startups?
Vicapsys' latest round of $330k is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Vicapsys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vicapsys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.